Net profit of IOL Chemicals & Pharmaceuticals rose 56.50% to Rs 29.97 crore in the quarter ended September 2025 as against Rs 19.15 crore during the previous quarter ended September 2024. Sales rose 7.95% to Rs 567.53 crore in the quarter ended September 2025 as against Rs 525.75 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales567.53525.75 8 OPM %10.067.91 - PBDT60.4843.88 38 PBT40.4925.94 56 NP29.9719.15 57 Powered by Capital Market - Live News

IOL Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live News

IOL Chemicals & Pharmaceuticals announced that the European Directorate for the Quality of Medicines & Health Care (EDQM) has issued a Certificate of Suitability for Company`s API product �Sitagliptin Phosphate Monohydrate� on 27 October 2025. Sitagliptin Phosphate Monohydrate is an oral antidiabetic medication used to control high blood sugar levels. Powered by Capital Market - Live News

Net profit of IOL Chemicals & Pharmaceuticals rose 13.21% to Rs 33.93 crore in the quarter ended June 2025 as against Rs 29.97 crore during the previous quarter ended June 2024. Sales rose 9.82% to Rs 551.69 crore in the quarter ended June 2025 as against Rs 502.38 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales551.69502.38 10 OPM %11.2610.17 - PBDT65.2856.34 16 PBT45.5139.52 15 NP33.9329.97 13 Powered by Capital Market - Live News

IOL Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 August 2025.Powered by Capital Market - Live News